Kura Oncology (KURA) Net Cash Flow (2010 - 2026)

Kura Oncology (KURA) has 17 years of Net Cash Flow data on file, last reported at -$110.0 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 36.48% year-over-year to -$110.0 million in Q1 2026; TTM through Mar 2026 was -$12.2 million, a 224.82% decrease from a year earlier, with the FY2025 full-year figure at -$75.4 million, down 140.27% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$110.0 million, down from $53.8 million in the prior quarter.
• Over the last five years, Net Cash Flow for KURA reached as high as $175.0 million in Q4 2024 and fell as low as -$173.2 million in Q1 2025.
• Historically, Net Cash Flow has averaged -$8.6 million across 5 years, with a median of $4.2 million in 2024.
• Across the five-year window, Net Cash Flow soared 24627.27% in 2022 and sank 4235.46% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$39.1 million in 2022, then surged by 121.92% to $8.6 million in 2023, then jumped by 1939.89% to $175.0 million in 2024, then tumbled by 69.25% to $53.8 million in 2025, then tumbled by 304.45% to -$110.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$110.0 million in Q1 2026, $53.8 million in Q4 2025, and $13.3 million in Q3 2025.